Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive RatReport as inadecuate




Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat - Download this document for free, or read online. Document in PDF available to download.

Background

A decreased prostatic blood flow could be one of the risk factors for benign prostatic hyperplasia-benign prostatic enlargement. The spontaneously hypertensive rat SHR shows a chronic prostatic ischemia and hyperplastic morphological abnormalities in the ventral prostate. The effect of silodosin, a selective alpha1A-adrenoceptor antagonist, was investigated in the SHR prostate as a prostatic hyperplasia model focusing on prostatic blood flow.

Methods

Twelve-week-old male SHRs were administered perorally with silodosin 100 μg-kg-day or vehicle once daily for 6 weeks. Wistar Kyoto WKY rats were used as normotensive controls and were treated with the vehicle. The effect of silodosin on blood pressure and prostatic blood flow were estimated and then the prostates were removed and weighed. The tissue levels of malondialdehyde MDA, interleukin-6 IL-6, chemokine C-X-C motif ligand 1-cytokine-induced neutrophil chemoattractant 1 CXCL1-CINC1, tumor necrosis factor-alpha TNF-α, transforming growth factor beta 1 TGF-β1, basic fibroblast growth factor bFGF and alpha-smooth muscle actin α-SMA were measured. The histological evaluation was also performed by hematoxylin and eosin staining.

Results

There was a significant increase in blood pressure, prostate weight, prostate body weight ratio PBR, tissue levels of MDA, IL-6, CXCL1-CINC1, TNF-α, TGF-β1, bFGF and α-SMA in the SHR compared to the WKY rat. The ventral prostate in the SHR showed the morphological abnormalities compared to the WKY rat. Prostatic blood flow was decreased in the SHR. However, treatment with silodosin significantly restored the decreased prostatic blood flow in the SHR. Moreover, silodosin normalized tissue levels of MDA, IL-6, CXCL1-CINC1, TNF-α, TGF-β1, bFGF and α-SMA, and it ameliorated ventral prostatic hyperplasia in the SHR excluding blood pressure. Silodosin decreased PBR but not prostate weight in the SHR.

Conclusions

Silodosin can inhibit the progression of prostatic hyperplasia through a recovery of prostatic blood flow.



Author: Shogo Shimizu, Takahiro Shimizu, Panagiota Tsounapi, Youichirou Higashi, Darryl T. Martin, Kumiko Nakamura, Masashi Honda, Keiji

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents